IceCure Medical receives patent approval for cryogen flow control technology.

IceCure Medical received a patent allowance from the China National Intellectual Property Administration for its "Cryogen Flow Control" invention, related to its XSense cryoablation system and probes. This technology enhances efficacy and precision in cryoablation procedures. Patents have been granted in Japan and are pending in the EU, US, and other major markets. The company's robust IP portfolio is becoming increasingly strategic as global interest in its platform and next-generation cryoablation technologies grows, following recent FDA marketing authorization for ProSense in low-risk breast cancer.